Traynor Capital Management Inc. Purchases 3,107 Shares of Pfizer Inc. (NYSE:PFE)

Traynor Capital Management Inc. increased its position in Pfizer Inc. (NYSE:PFE) by 16.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,720 shares of the biopharmaceutical company’s stock after purchasing an additional 3,107 shares during the quarter. Traynor Capital Management Inc.’s holdings in Pfizer were worth $625,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Front Street Capital Management Inc. boosted its position in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares in the last quarter. Graves Light Lenhart Wealth Inc. boosted its position in Pfizer by 1.4% during the 2nd quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC boosted its position in Pfizer by 5.2% during the 2nd quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 284 shares in the last quarter. Castleview Partners LLC boosted its position in Pfizer by 2.4% during the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 287 shares in the last quarter. Finally, United Bank boosted its position in Pfizer by 0.6% during the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after acquiring an additional 290 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Barclays decreased their price objective on Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Finally, UBS Group decreased their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a report on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Performance

Shares of NYSE PFE traded down $0.03 during trading on Friday, reaching $27.75. 40,466,657 shares of the company traded hands, compared to its average volume of 47,662,984. The firm’s fifty day simple moving average is $27.46 and its 200 day simple moving average is $29.46. The stock has a market cap of $157.14 billion, a P/E ratio of 77.08, a PEG ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12-month low of $25.61 and a 12-month high of $42.22. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the business posted $1.14 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.